The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -14,495,028 |
| Depreciation | 291,908 |
| Amortization of right-of-use assets | 406,992 |
| Stock-based compensation | 127,374 |
| Fair value of shares issued in exchange for services | 99,040 |
| Non-cash effect of reverse stock split | 704 |
| Advances, deposits, and other current assets | -193,507 |
| Accounts payable and accrued liabilities | -521,121 |
| Net cash used in operating activities | -13,896,624 |
| Purchases of property and equipment | 280,572 |
| Net cash (used in) provided by investing activities | -280,572 |
| Proceeds from sale of common stock equity, net of issuance costs | 13,628,070 |
| Proceeds from issuance of common stock upon exercise of warrants | 3,467,695 |
| Issuance costs of stock dividend | 10,277 |
| Net cash provided by financing activities | 17,085,488 |
| Net change in cash, cash equivalents | 2,908,292 |
| Cash and cash equivalents at the beginning of year | 5,872,767 |
| Cash and cash equivalents at the end of year | 8,781,059 |
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)